Literature DB >> 3876396

Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for the treatment of chancroid in Thailand.

D N Taylor, C Pitarangsi, P Echeverria, K Panikabutra, C Suvongse.   

Abstract

A single dose of ceftriaxone (250 mg) administered intramuscularly was compared with trimethoprim-sulfamethoxazole (TMP-SMZ; 160/800 mg) administered orally twice daily for seven days or with a single dose of TMP-SMZ (640/3,200 mg) administered orally for the treatment of chancroid in men in Thailand. Haemophilus ducreyi was isolated from 79 (48%) of 164 men with a clinical diagnosis of chancroid. For men with ulcers that were culture positive for H. ducreyi, rates of cure were 100% in 25 men treated with ceftriaxone, 87% in 23 men given TMP-SMZ for seven days, and 55% in 31 men given TMP-SMZ in a single dose. For men with ulcers that were culture negative for H. ducreyi, rates of cure were 100% in 29 men treated with ceftriaxone, 66% in 32 men given TMP-SMZ for seven days, and 63% in 24 men given TMP-SMZ in a single dose. The MIC50 of the three antibiotics for 94 isolates of H. ducreyi were as follows: 0.004 micrograms/ml for ceftriaxone, 16 micrograms/ml for trimethoprim, and greater than 512 micrograms/ml for sulfamethoxazole. Our study indicates that ceftriaxone in a single dose of 250 mg is effective, but that TMP-SMZ, even when given in a standard seven-day regimen, is not effective treatment for chancroid in Thailand.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876396     DOI: 10.1093/infdis/152.5.1002

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 3.  Treatment of chancroid.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Treating chancroid: summary of studies in southern Africa.

Authors:  R C Ballard; M O Duncan; H G Fehler; Y Dangor; F L Exposto; A S Latif
Journal:  Genitourin Med       Date:  1989-01

5.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Single dose trimethoprim-sulphamethoxazole for treatment of chancroid.

Authors:  B Kumar; G Dawn
Journal:  Genitourin Med       Date:  1995-04

7.  Emergence of Haemophilus ducreyi resistance to trimethoprim-sulfamethoxazole in Rwanda.

Authors:  E Van Dyck; J Bogaerts; H Smet; W M Tello; V Mukantabana; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

Authors:  J S Knapp; A F Back; A F Babst; D Taylor; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Enhanced recovery of Haemophilus ducreyi from clinical specimens by incubation at 33 versus 35 degrees C.

Authors:  G P Schmid; Y C Faur; J A Valu; S A Sikandar; M M McLaughlin
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

10.  Single-dose ceftriaxone for chancroid.

Authors:  M I Bowmer; H Nsanze; L J D'Costa; J Dylewski; L Fransen; P Piot; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.